SNY's Subcutaneous Sarclisa Outperforms IV Formulation in Cancer Study
Portfolio Pulse from
Sanofi's subcutaneous formulation of Sarclisa has demonstrated non-inferiority compared to the intravenous version in a late-stage study for treating relapsed, refractory multiple myeloma.
January 10, 2025 | 4:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Sanofi's subcutaneous Sarclisa formulation has shown non-inferiority to the intravenous version in a late-stage study for multiple myeloma, potentially enhancing its market appeal.
The successful study results for the subcutaneous version of Sarclisa could lead to increased adoption and preference over the IV formulation, potentially boosting Sanofi's market share and revenues in the oncology sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100